Amyloidosis Incidence in High-Risk Cardiac Device Patients

Description

This single-practice prospective cohort study aims to enhance the diagnosis of cardiac amyloidosis in high-risk patients undergoing standard cardiac device implantation. By analyzing chest wall fat tissue, which is usually discarded, we aim to determine the diagnostic yield of such biopsies for amyloidosis and to develop a predictive screening model based on clinical, lab, and imaging data. The study, running from December 2023 to December 2024, expects to enroll 100 patients and may provide a new, non-invasive diagnostic avenue for this condition.

Conditions

Amyloid, Cardiac Amyloidosis, Amyloidosis Cardiac, Systemic Amyloidosis, AL Amyloidosis, Infiltrative Cardiomyopathy, Amyloid, ATTR Amyloidosis Wild Type

Talk to us

Study Overview

On this page

Study Details

Study overview

This single-practice prospective cohort study aims to enhance the diagnosis of cardiac amyloidosis in high-risk patients undergoing standard cardiac device implantation. By analyzing chest wall fat tissue, which is usually discarded, we aim to determine the diagnostic yield of such biopsies for amyloidosis and to develop a predictive screening model based on clinical, lab, and imaging data. The study, running from December 2023 to December 2024, expects to enroll 100 patients and may provide a new, non-invasive diagnostic avenue for this condition.

Histopathological Incidence of Amyloidosis in High-Risk Patients Undergoing Cardiac Device Implantation

Amyloidosis Incidence in High-Risk Cardiac Device Patients

Condition
Amyloid
Intervention / Treatment

-

Contacts and Locations

Overland Park

Midwest Heart & Vascular Specialists, Overland Park, Kansas, United States, 66211

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients who are 40 years of age or older
  • * Patients who are able and willing to provide informed consent
  • * Patients who are scheduled for CIED implantation within the study period and with clinical lab and imaging features suggestive of cardiac amyloidosis
  • * Individuals below the age of 40.
  • * Persons who are unable to consent or who do not consent to participate.
  • * Patients who have already been diagnosed with cardiac amyloidosis prior to the study

Ages Eligible for Study

40 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Midwest Heart & Vascular Specialists,

Vasvi Singh, MD, PRINCIPAL_INVESTIGATOR, Midwest Heart & Vascular Specialists

Study Record Dates

2024-12-31